Indra Sanyal
Founder bij Teva Biopharmaceuticals USA, Inc.
Profiel
Indra Sanyal is the founder of Teva Biopharmaceuticals USA, Inc. which was founded in 2005, where he holds the title of Chief Technology Officer.
Dr. Sanyal's former jobs include Vice President-Process Development at Human Genome Sciences, Inc. and Principal at Diversa Corp.
Dr. Sanyal's education history includes a doctorate from The Johns Hopkins University and a graduate degree from the Indian Institute of Technology Bombay.
Actieve functies van Indra Sanyal
| Bedrijven | Functie | Begin |
|---|---|---|
Teva Biopharmaceuticals USA, Inc.
 Teva Biopharmaceuticals USA, Inc. BiotechnologyHealth Technology Teva Biopharmaceuticals USA, Inc. develops and commercializes biological products. It uses albumin-fusion technology to develop and commercialize certain albumin-fusion proteins for therapeutic use. The company was founded by Craig A. Rosen, Steven C. Mayer, Indra Sanyal and Mark A. Rampy in 2005 and is headquartered in Rockville, MD. | Founder | 01-01-2005 |
Eerdere bekende functies van Indra Sanyal
| Bedrijven | Functie | Einde |
|---|---|---|
Diversa Corp.
 Diversa Corp. Miscellaneous Commercial ServicesCommercial Services Diversa searches high and low for DNA. In its quest to develop new enzymes and other active biological compounds, the biotechnology company collects and catalogs the DNA of organisms in diverse environments (from manure piles to tropical islands). A variety of manufacturers license these compounds from the firm to develop or improve their products, which include detergents, oils, animal feeds, and pharmaceuticals. Diversa's products include enzymes for the oil and gas industry | Corporate Officer/Principal | - |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
Opleiding van Indra Sanyal
| The Johns Hopkins University | Doctorate Degree |
| Indian Institute of Technology Bombay | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Diversa Corp.
Diversa Corp. Miscellaneous Commercial ServicesCommercial Services Diversa searches high and low for DNA. In its quest to develop new enzymes and other active biological compounds, the biotechnology company collects and catalogs the DNA of organisms in diverse environments (from manure piles to tropical islands). A variety of manufacturers license these compounds from the firm to develop or improve their products, which include detergents, oils, animal feeds, and pharmaceuticals. Diversa's products include enzymes for the oil and gas industry | Commercial Services |
Teva Biopharmaceuticals USA, Inc.
Teva Biopharmaceuticals USA, Inc. BiotechnologyHealth Technology Teva Biopharmaceuticals USA, Inc. develops and commercializes biological products. It uses albumin-fusion technology to develop and commercialize certain albumin-fusion proteins for therapeutic use. The company was founded by Craig A. Rosen, Steven C. Mayer, Indra Sanyal and Mark A. Rampy in 2005 and is headquartered in Rockville, MD. | Health Technology |
